Phenotyping Alzheimer's disease with blood tests
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Affordable and accessible tools could be used for screening and therapy monitoring
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some pTau fragments (pTau181, pTau217 and pTau231) in the blood have been shown to accurately reflect brain pathology and are rapidly emerging as biomarkers 148 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [148]
In the citing paper
“Blood levels of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) may accurately reflect neurodegeneration and neuroinflammation, respectively 148 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [148]
Citations
Cites
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationDominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Palmqvist, S., Tideman, P., Cullen, N., Zetterberg, H., Blennow, K., Initiative, T. A. D. N., Dage, J. L., Stomrud, E., Janelidze, S., Mattsson-Carlgren, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01348-z · Cited by 524
Self-citationChatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01137-1 · Cited by 439
Self-citationBlood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200861 · Cited by 437
Research works printed but not linked: 1
- A. Keshavan , Brain 144, 434 (2021).
Cited by
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., et al. (2023) · Brain · doi:10.1093/brain/awac333 · Cited by 522
Self-citationReynolds, C. F., Jeste, D. V., Sachdev, P. S., & Blazer, D. G. (2022) · World Psychiatry · doi:10.1002/wps.20996 · Cited by 465
Ashton, N. J., Puig‐Pijoan, A., Milà‐Alomà, M., Fernández‐Lebrero, A., García‐Escobar, G., González‐Ortiz, F., Kac, P. R., Brum, W. S., Benedet, A. L., Lantero‐Rodriguez, J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12841 · Cited by 230
“1,25,26 This will be of significant importance given the emergence of disease-modifying treatments for AD.”
BackgroundSelf-citationPichet Binette, A., Janelidze, S., Cullen, N., Dage, J. L., Bateman, R. J., Zetterberg, H., Blennow, K., Stomrud, E., Mattsson‐Carlgren, N., & Hansson, O. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12787 · Cited by 226
Self-citationKim, B., Kim, S., Nam, Y., Park, Y., Shin, S. M., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00465-w · Cited by 187
Wallensten, J., Ljunggren, G., Nager, A., Wachtler, C., Bogdanović, N., Petrović, P., & Carlsson, A. C. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01308-4 · Cited by 123
“This is particularly relevant given the proposal that plasma biomarkers, such as phosphotau, neurofilament light chain protein (NfL) and glial fibrillary acidic protein (GFAP), may serve as routine diagnostic biomarkers in a near future [10].”
BackgroundEide, P. K., Lashkarivand, A., Pripp, A. H., Valnes, L. M., Hovd, M. H., Ringstad, G. A., Blennow, K., & Zetterberg, H. (2023) · Nature Communications · doi:10.1038/s41467-023-37685-5 · Cited by 78
“…acid-long A β peptides (A β 40 and − 42), tau protein variants, glial fi brillary acidic protein (GFAP), and neuro fi lament light (NfL), have emerged as diagnostic biomarkers of neurodegenerative diseases, currently in particular for Alzheimer ’ s disease (AD) and post-traumatic brain injuries 3,4 .”
Self-citationColey, N., Giulioli, C., Aisen, P. S., Vellas, B., & Andrieu, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101777 · Cited by 62
Zicha, S., Bateman, R. J., Shaw, L. M., Zetterberg, H., Bannon, A. W., Horton, W. A., Baratta, M., Kolb, H. C., Dobler, I., Mordashova, Y., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12697 · Cited by 58
Pichet Binette, A., Palmqvist, S., Bali, D., Farrar, G., Buckley, C. J., Wolk, D. A., Zetterberg, H., Blennow, K., Janelidze, S., & Hansson, O. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00990-0 · Cited by 52
Self-citationTrajectories and contributing factors of neural compensation in healthy and pathological aging
Bunzeck, N., Steiger, T. K., Krämer, U. M., Luedtke, K., Marshall, L., Obleser, J., & Tune, S. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105489 · Cited by 46
“Finally, amyloid-β and pTau are important markers of Alzheimer ’ s disease (AD), including preclinical AD and MCI (Ashton et al., 2023; Blennow, 2021; Mil ` a-Alom ` a et al., 2022), that can be quantified via blood samples.”
BackgroundHighly Sensitive Serum Protein Analysis Using Magnetic Bead-Based Proximity Extension Assay
Zhang, P., Hu, J., Park, J. S., Hsieh, K., Chen, L., Mao, A., & Wang, T. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c02684 · Cited by 35
Gerards, M., Schild, A., Meiberth, D. U., Rostamzadeh, A., Vehreschild, J. J., Wingen-Heimann, S. M., Johannis, W., Adami, P. V. M., Onur, O. A., Ramírez, A., et al. (2022) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000524390 · Cited by 31
Self-citationA critical appraisal of blood-based biomarkers for Alzheimer’s disease
Lista, S., Mapstone, M. E., Caraci, F., Emanuele, E., López‐Ortiz, S., Martín-Hernández, J., Triaca, V., Imbimbo, C., Gabelle, A., Mielke, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102290 · Cited by 32
Dong, Y., Hou, T., Li, Y., Liu, R., Cong, L., Liu, K., Liu, C., Han, X., Ren, Y., Tang, S. H., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230932 · Cited by 29
“Specifically, plasma A (cid:2) 42 /A (cid:2) 40 ratio, which correlates with brain amyloid PET load, is considered a reliable biomarker of A (cid:2) pathology in the brain, whereas plasma neurofilament light chain (NfL) and total tau (t-tau) are biomarkers for neurodegeneration [6–8].”
Self-citationBruse, N., Motos, A., van Amstel, R. B. E., Bie, E. M. D. D. D., Kooistra, E. J., Jansen, A., van Lier, D. P. T., Kennedy, J. N., Schwarzkopf, D., Thomas-Rüddel, D. O., et al. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07593-3 · Cited by 28
“Cor-ticosteroid therapy was started at a median [IQR] of 5 [2–9] days after ICU admission and was administered for 5 [3–7] days.”
Grossmann, K. (2022) · Biomedicines · doi:10.3390/biomedicines10081890 · Cited by 26
“By its progress in developing sensitive blood-based biomarkers for AD, blood phenotyping can be an attractive and cost-saving alternative or supplement to MRI/PET scans and invasive CSF analyses in the near future [60,155].”
BackgroundMethodInfluentialAlzheimer's Disease Diagnosis in the Preclinical Stage: Normal Aging or Dementia
Marvi, F., Chen, Y.-H., & Sawan, M. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2024.3376835 · Cited by 30
“In addition, the present tools for investigating physical behavior are bulky, textile-based devices, which are not useful for long-term monitoring [15], [16].”
Plasma p-tau181 and amyloid markers in Alzheimer’s disease: A comparison between Lumipulse and SIMOA
Quaresima, V., Pilotto, A., Trasciatti, C., Tolassi, C., Parigi, M., Bertoli, D., Mordenti, C., Galli, A., Rizzardi, A., Caratozzolo, S., et al. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.08.007 · Cited by 22
“The recent development of plasma biomarkers using Single Molecule Array (SIMOA) technique is changing the era of the diagnosis of AD potentially shifting from CSF to blood assessments (Blennow, 2021; Leuzy et al., 2021a; Zetterberg and Blennow, 2021).”
Self-citationSanotra, M. R., Huang, W., Silver, S. D., Lin, C., Chang, T.-C., Nguyen, D. P. Q., Lee, C., Kao, S., Shieh, J. C.-C., & Lin, Y. (2021) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.12.005 · Cited by 19
Imaging and Fluid Biomarkers of Alzheimer Disease: Complementation Rather Than Competition
Drzezga, A. E., & Barthel, H. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270152 · Cited by 20
A Novel Panel of Plasma Proteins Predicts Progression in Prodromal Alzheimer’s Disease
Araújo, D. C., Initiative, A. D. N., Veloso, A., Gomes, K. B., de Souza, L. C., Ziviani, N., & Caramelli, P. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220256 · Cited by 20
“Despite these developments, prediction of disease progression through minimally invasive and cheaper methods such as plasma biomarkers has been less explored and requires further investigation [12].”
Lu, J., Wang, J., Wu, J., Zhang, H., Ma, X., Zhu, Y., Wang, J., Yang, Y., Xiao, Z., Li, M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14245 · Cited by 13
From pixels to prognosis: radiomics and AI in Alzheimer’s disease management
Peng, D., Huang, W., Liu, R. P., & Zhong, W. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1536463 · Cited by 17
Morgado, B., Klafki, H., Bauer, C., Steiert, A., Waniek, K., Lachmann, I., Osterloh, D., Esselmann, H., Hansen, N., Schuchhardt, J., et al. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02123-8 · Cited by 6
“…and robust measurements of AD biomarkers in blood through reliable high-throughput platforms have the potential for a wide range of applications [1 ] including screening, early diagnosis, track - ing progression, and monitoring the efficacy of the recent developments regarding disease-modifying…”
Combining Multiple Factors to Predict Alzheimer’s Disease
Gao, X., Wang, J., Wang, Y., & Bu, X. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00868-z · Cited by 5
“And plasma amyloid has good diagnostic and predictive value, especially the Ab42:Ab40 ratio and amyloid precursor protein (APP)669-711:Ab42 [6, 7].”
BackgroundLuo, Y., Liu, X., Liu, Y., Xu, T., & Zhang, X. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117157 · Cited by 5
Shim, Y. (2023) · Current Alzheimer Research · doi:10.2174/0115672050284054240119101834 · Cited by 6
Exploring exosomes to provide evidence for the treatment and prediction of Alzheimer’s disease
QUAN, X., MA, X., LI, G., FU, X., LI, J., & ZENG, L. (2023) · Biocell · doi:10.32604/biocell.2023.031226 · Cited by 4
Solis‐Urra, P., Rodríguez‐Ayllón, M., Álvarez-Ortega, M., Molina‐Hidalgo, C., Molina‐García, P., Arroyo‐Avila, C., García‐Hermoso, A., Collins, A. M., Jain, S., Gispert, J. D., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230586 · Cited by 4
“In addition, alterations in the concentration of A (cid:2) species can be detected in cerebrospinal fluid (CSF) and, more recently, ultra-sensitive techniques have been developed to also measure them in plasma [3].”
An appraisal at a glance of metallome and disease biomarkers
López, R., Pereira, F. J., & Aller, A. J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117931 · Cited by 4
Alzheimer's disease plasma biomarkers in the Midwestern Amish
Wang, P., Song, Y. E., Lynn, A., Miskimen, K. L. S., Gulyayev, A. V., Prough, M. B., Dorfsman, D. A., Laux, R. A., Fuzzell, S. L., Hochstetler, S. D., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70328 · Cited by 3
Fan, X., Ye, X., Xu, J., Mao, T., Zhang, R., Zhou, X., Yeung, C. C. K. A., Li, C., Chang, R. C., Lin, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202509376 · Cited by 3
Quo Vadis translational neuroscience?
Dere, E. (2026) · Translational Neuroscience · doi:10.1515/tnsci-2025-0393 · Cited by 1
Li, X., Hou, S., He, Z., Sun, Y., Sun, Y., Yao, Y., Long, Z., Duan, C., & Zhou, J. (2026) · Chemical & Biomedical Imaging · doi:10.1021/cbmi.6c00055 · Cited by 1
Heritability of Alzheimer's disease–related plasma biomarkers in the Amish population
Wang, P., Song, Y. E., Lynn, A., Miskimen, K. L. S., Gulyayev, A. V., Prough, M. B., Dorfsman, D. A., Laux, R. A., Fuzzell, S. L., Hochstetler, S. D., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70388 · Cited by 3
CSF 14-3-3ζ is associated with tau pathology and elevated across the Alzheimer’s disease continuumPreprint
Qiang, Q., Skudder‐Hill, L., Toyota, T., Huang, Z., Wei, W., & Adachi, H. (2022) · Research Square · doi:10.21203/rs.3.rs-2229567/v1
CSF 14-3-3ζ is associated with tau pathology and elevated across the Alzheimer’s disease continuumPreprint
Qiang, Q., Skudder‐Hill, L., Toyota, T., Huang, Z., Wei, W., & Adachi, H. (2022) · Research Square · doi:10.21203/rs.3.rs-2229567/v2
Puig‐Pijoan, A. (2024) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Surface-specific spectroscopy of lipids and proteins
Maltseva, D. (2022) · UvA-DARE (University of Amsterdam)
Perez‐Pons, M., Benitez, I. D., Molinero, M., García‐Hidalgo, M. C., Rodríguez‐Muñoz, C., Sánchez-Rodríguez, M., Belmonte, T., Vilanova, M. R., Moreno, P. N., Moreno, M. P., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116951
Metadata
- Authors
- Blennow, K.
- Affiliations
- University of Gothenburg (SE)
- Corresponding author
- Blennow, Kaj
- ORCID
- Blennow, Kaj
- Venue
- Science
- Published
- 2021-08-06
- Volume
- 373
- Issue
- 6555
- Pages
- 626-628
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3191044320
- Cited by
- 41
- References
- 15
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 14 · 2021: 1
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Keywords
- Alzheimer's disease, blood analysis, phenotyping, biomarkers, disease screening, treatment monitoring, liquid biopsy
- MeSH terms
- Alzheimer Disease, Humans, Peptide Fragments, Phenotype, Phosphorylation, Biomarkers, Amyloid beta-Peptides, Cerebral Amyloid Angiopathy, tau Proteins, Positron-Emission Tomography, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.